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Treatment with anti-idiotypic (anti-Id) a antibodies can, under certain experimental 
conditions, induce lymphocytes and antibodies of  complementary specificity. Injection 
of minute  amounts  of anti-Id  antibodies  has  been  shown  in  several  experimental 
systems to induce antigen-specific helper T  cells (1-4) and to enhance the expression 
of the corresponding Id in subsequent antibody responses (5-9). More recently (10), 
administration  of anti-Id  has  been  reported  to  induce  the  production of antigen- 
binding Id-positive molecules in the absence of exposure to antigen. Collectively, these 
experiments provide clear evidence that  idiotypic regulation of the immune system 
can occur and that antigen-independent mechanisms exist for the expansion of B cell 
clones bearing the appropriate Id. The application and extension of these findings to 
the induction of immunity to microbial agents is of obvious interest. 
In these studies, we attempted to immunize mice against African trypanosomiasis 
with anti-Id antibodies. Infection with African trypanosomes, the etiological agents of 
sleeping sickness, is characterized by a cycling parasitemia, with each cycle consisting 
of increasing parasitemia, host antibody production, parasite clearance, and appear- 
ance  of trypanosomes  of different  variable  antigen  types  (VAT).  This  antigenic 
variation apparently occurs spontaneously, with antibody playing a selective role in 
the elimination of major VAT. It is the ability of the parasite to undergo antigenic 
variation  that  is  responsible  for the cycling parasitemia  and  the chronicity of the 
infection (11,  12). We have chosen experimental African trypanosomiasis as a model 
for anti-Id-induced microbial immunity because (a)  immunity is known to be medi- 
ated by antibody (13,  14), and (b) protective monoclonal antibodies (Id) can be raised 
against the variable surface antigens of these parasites. We report here that adminis- 
tration  of anti-Id  antibodies  raised  against  three  such  protective  Id  will  induce 
complete or partial immunity to infection with the homologous clone of Trypanosoma 
rhodesiense. To our knowledge,  this  is  the  first  demonstration  that  anti-Id-mediated 
regulation of Id expression can substitute for antigen in the induction ofantimicrobial 
immunity. 
* Address correspondence  to Dr. David L. Sacks, Laboratory  of Parasitic Diseases, National Institute of 
Allergy and Infectious  Disease, National Institutes of Health, Building 5, Bethesda, MD 20205. 
1  Abbreviations used in this paper."  IBC, idiotype~binding  capacity; Id, idiotype; anti-Id, anti-idiotypic; 
IFA, indirect  immunofluorescence  assay; NMIg, normal mouse immunoglobulin; PBS, phosphate-buffered 
saline; RIA, radioimmunoassay; SRBC, sheep erythrocytes;  VAT, variable antigen type. 
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Materials  and  Methods 
Animals.  BALB/cJ and SJL/J female mice, 6-8 wk old, were purchased from The Jackson 
Laboratory, Bar Harbor, ME. 
Trypanosomes.  The derivation of trypanosome clone WRATat  1.1 from a human isolate of 
Trypanosoma brucei rhodesiense has been described (15). Infection of mice with this clone results in 
chronic  infection,  characterized  by  relapsing peaks  of parasitemia and  death  of the  mice 
between  100  and  150  d.  Another clone of T.  rhodesiense, obtained from  Dr.  Peter Gardiner, 
National Institutes of Health, designated EATRO 1886, clone NIHTat  1, bears a VAT that is 
non-cross-reactive with WRATat 1.1. 
Monoclonal Antibodies.  The  derivation,  specificity, and  biological activity of monoclonal 
antibodies  7Hll,  llD5,  and  B7B1  will  be  described  in  detail  (K.  Esser,  manuscript  in 
preparation). Briefly, all are derived from fusions of WRATat  1.1 immune spleen cells to the 
P3/X63-AgS, IgGl-secreting myeloma line (16). All are IgG1, reacting with the VAT of clone 
WRATat  1.1. In addition, all can  neutralize parasite infectivity, as determined by in  vivo 
neutralization and passive transfer. The antibodies used for immunization were purified from 
ascites fluid by affinity chromatography on protein-A Sepharose 4B (Pharmacia Fine Chemicals, 
Div. of Pharmacia Inc., Piscataway, N  J) and elution with 0.2 M  glycine, pH 3.0, 0.5 M  NaCl, 
followed by dialysis against phosphate-buffered saline (PBS). 
Preparation and Purification of Anti-Idiotypic Antibodies.  SJL mice were immunized by footpad 
and subcutaneous injections of 75/~g of purified 7H11,  11D5, or B7B1  protein emulsified with 
twice the volume of complete Freund's adjuvant (17). The mice were boosted 2 wk later with 
75/zg antigen in incomplete Freund's adjuvant, followed 2 wk later by 75 ~g in saline. Tail 
bleedings commenced 2 wk after the last boost and were tested for hemagglutination of Id, 
normal  BALB/c  IgG  (NMIg),  or  MOPC  21  myeloma protein  (IgG1  i¢)  coupled  to  sheep 
erythrocytes (SRBC), as described (18).  Serum from bleedings within each group were pooled 
and  absorbed with  normal  BALB/c  IgG  and  MOPC  21  coupled  to  Sepharose  to  remove 
activity against heavy chain allotype and MOPC 21  Id. Complete absorbtion was confirmed 
by failure of absorbed sera to hemagglutinate NMIg and MOPC 21-coupled SRBC. The IgG1 
fraction of each anti-Id antisera was purified by elution from protein-A Sepharose with 0.1 M 
sodium citrate, pH 6.0 (19). The IgG1 fraction of normal SJL sera was similarly prepared. The 
Id-binding capacity (IBC) of each 125I-labeled IgG1 fraction was determined by calculation of 
the percent IgGx anti-Id completely absorbed by the homologous Id-coupled SRBC preparation. 
MOPC 21 and NMIg-coupled SRBC were used as control absorbants. It was determined that 
of the IgG1  fractions of anti-7H11, -llD5, -B7B1  Id,  11%, 9%, and 6%, respectively, reacted 
specifically with their homologous idiotypes. 
Treatment of Mice with Anti-Id.  BALB/c mice, 2-4 mo of age, were treated with various doses, 
calculated with respect to IBC, of the IgG1 fractions of each of the three anti-Id. The required 
concentration of one anti-Id was prepared, pooled with the identical concentration of the other 
two, and then injected intraperitoneally into mice in 0.5 ml saline. Mice were test bled from tail 
veins periodically after anti-Id treatment and infection to monitor serum Id levels. 
Infection with T  rhodesiense.  Control and anti-Id-treated mice were infected with 100 trypan- 
osomes  of clone  WRATat  1.1  or  NIHTat  1,  as  described  (15).  Blood  parasitemias were 
determined daily by examination of wet tail blood smears under high power (400×). Counts 
were converted to trypanosomes per milliliter, using a calibration curve. 
Determination of  VAT.  An  indirect  immunofluorescenee  assay  (IFA)  was  used  to  detect 
specific VAT of individual trypanosomes in  potentially mixed populations of T.  rhodesiense 
organisms (20). Trypanosomes appearing during the first peak of parasitemia during WRATat 
1.1 infection were examined for VAT using thin smears of trypanosome-infected mouse blood. 
The  antigen slides were air dried, fixed in acetone, and  stored at  -20°C.  Thawed  antigen 
slides, overlaid with  individual or pooled anti-WRATat  1.1  monoclonal antibodies, diluted 
1/20, plus a  1/80 dilution of a mouse monoelonal antibody specific for a common trypanosome 
antigen, were incubated in a  moist chamber at 37°C  for 30  min. The slides were washed in 
PBS for 5 min, air dried, and overlaid with fluorescein-conjugated goat anti-mouse immuno- 
globulin  (N.  L.  Cappel  Laboratories, Cochranville,  PA)  diluted  1:40  in  PBS.  Slides were 
incubated  at  37°C  for an  additional 30  min,  washed,  and  coverslips applied with  pH  7.2 
buffered  glycerol. Organisms  binding  monoclonal  anti-VAT  antibodies  exhibited  intense, 1110  IMMUNIZATION WITH ANTI-IDIOTYPIC ANTIBODIES 
uniform fluorescence and were readily distinguished from those binding only the monoclonal 
antibody against the common trypanosome determinant. Detection of the NIHTat  1 VAT was 
accomplished by an identical method, using a VAT-specific rabbit antiserum and fluorescein- 
conjugated goat anti-rabbit immunoglobulin. 
Radioimmunoassay (RIA).  Id concentrations in sera were determined in a solid-phase RIA in 
which the capacity of serum to inhibit the binding of 125I-labeled Id to the homologous anti-Id 
was measured  (21).  Briefly, microwell plates were coated with protein A  Sepharose-purified 
anti-Id (50 #1,  150 #gm/ml) for 18 h at 4°C, followed by three washings with PBS. The plates 
were incubated for 1 h with 50% fetal calf serum in PBS and, after three washings, incubated 
for 3 h at 4°C with saline, various proteins, or sera either undiluted or diluted 1:10 in saline. 
After three washings, the homologous Id, labeled with x25I by the chloramine T  method (22), 
was added to each well (50,000  cpm/50 #1) and incubated 3 h at 4°C. The plates were washed 
at least five times, and each well was counted in a Nuclear-Chicago gamma counter (Nuclear- 
Chicago Corp., Des Plaines, IL). The assay was standardized with known concentrations of 
purified cold homologous Id as inhibitors. 
Results 
Specificity of Anti-Id Antibodies.  The binding of radiolabeled monoclonal antibodies 
by  the  homologous  anti-Id  was  shown  to  be  restricted  in  each  case  to  idiotypic 
determinants  by the failure of NMIg and  MOPC  21  to inhibit binding  (Fig.  1).  In 
addition, the inability in each case of the heterologous Id to inhibit binding indicates 
that the Id are non-cross-reactive and derived from distinct clones, each of which has 
specificity for the WRATat  1.1 VAT. 
Immunization with Anti-Id Antibodies.  After previous studies in which the subclass of 
anti-Id was  found  to  influence  its  regulatory effect  (1,  23,  24),  IgG1,  shown  to  be 
capable  of priming  for  Id  expression, was  purified  from  each  of the  three  anti-Id 
antisera as well as from control, normal SJL sera. We chose to administer the three 
IgG1  anti-Id  together  to  improve  the  chances  of  inducing  immunity.  In  a  pilot 
experiment  for these studies, we found  that  treatment  with  100  ng or  10  ng of the 
three  anti-Id  3-4  wk  before  challenge  had  no  effect  on  the  outcome  of infection, 
whereas  1 #g  appeared  to  induce  protection  in  some  animals.  In  the  experiments 
described  here,  doses  ranging  from  250  ng  to  4/~g  and  administered  3  wk  before 
challenge were chosen in an attempt to optimize the conditions required for protection. 
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Infection  of BALB/c  mice  with  100  cloned  WRATat  1.1  organisms  results  in 
fluctuating waves of blood parasitemia of which 95-100% of the parasites in the first 
peak bear the original VAT (11).  Trypanosomes in the subsequent  peaks bear new 
VAT; therefore, any immunity induced by anti-Id administration will presumptively 
affect  only  the  first  wave  parasitemia.  We  expected  the  successful  induction  of a 
specific  anti-VAT  response  to  have  three  alternative  effects  on  the  infection:  (a) 
complete protection, in which the infecting VAT is eliminated before new VAT are 
able  to  emerge and  no  blood  parasitemia  is  ever observed,  (b)  reduced  first  wave 
parasitemia, or  (c)  selection against  parasites bearing the original VAT in  favor of 
different VAT in the first wave, observed as VAT switching. We define parasitemia 
as reduced  when  the peak parasitemia in  the anti-Id-treated group is less than  the 
lowest  peak parasitemia in  the  controls.  In addition,  we  define  VAT switching  as 
having occurred when <10% of the organisms in the first peak bear the original VAT, 
as defined by reaction with monoclonal reagents in the IFA. 
In fact, what we observed were all three effects. As shown in Table I, mice treated 
with  normal  SJL  IgG1 at  a  dose  equivalent  to  the  total  protein  contained  in  the 
pooled anti-Id at the 1 #g IBC concentration had typical primary parasitemias, except 
for an aberrant  mouse in  which  the original  VAT was not  expressed.  Of the mice 
treated with either 250 ng,  1 #g, or 4 #g of the three anti-Id, within each group were 
mice that  had  normal  infections,  no  detectable blood parasitemia,  reduced  parasi- 
temia,  or switched  VAT.  No obvious dose effect could  be appreciated.  Considered 
together, of the 30 mice treated with anti-Id, 63% had altered infections, with complete 
protection (23%) and VAT switching (27%) being the dominant effects. The first wave 
parasitemia profiles of the controls (excluding the one aberrant mouse), and the anti- 
Id-treated mice with reduced  parasitemia are shown  in  Fig.  2.  Also included  is the 
course of primary parasitemia of those mice with switched VAT, for which the peak 
parasitemia was typically delayed by 1 d. 
Expression  of 7H11  Id Pre- and Postinfection.  Sera obtained pre- and post-challenge 
were analyzed in a  competitive RIA for the presence of each of the three Id. In Fig. 
3,  individual  mice  are  grouped  according  to  the  outcome  of initial  parasitemia. 
Control  mice that  received  normal  SJL IgG1 and  had  normal  infection  had  either 
very low or undetectable  levels of the  7H 11  Id  in  their sera,  both  before and  3  d 
postinfection (Fig. 3 a). The detection of low levels of the 7H 11  Id in the majority of 
mice 2 wk after infection suggests that the Id is normally expressed in response to the 
first wave parasites that bear the WRATat  1.1  VAT. Of the mice that were treated 
with anti-Id and had normal infection, there was variable expression of the Id 2 wk 
TABLE I 
Outcome of Primary Parasitemia in BALB/c Mice Immunized with Anti-Idiotypic 
Antibodies 
Altered in-  Treatment  Normal  Protected Reduced  Switched  fection/total 
Normal SJL IgG~  9  0  0  1  1/10 
Anti-Id IgGl 
250 ng  4  2  1  3  6/10 
1 gm  5  3  1  l  5/10 
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after treatment and before infection. However, all had low or undetectable levels  of 
the 7H 11 Id when examined 3 d after challenge. In contrast, relatively high levels  of 
the Id were found 3 d after challenge in all protected mice and all mice that displayed 
VAT switching. Within the switched group, the only mouse in which this Id was not 
found at this time was the aberrant control. The 7H11  Id was also found before or 
early in infection in three of four mice that experienced reduced parasitemia.  In all 
four mice, the levels of Id were highest 2 wk postinfection, subsequent to peak antigen 
exposure, whereas in the other affected groups in which the concentration of WRATat 
1.1  VAT remained minimal, the levels of 7H 11 Id had generally declined after 2 wk 
of infection. 
Thus anti-Id administration appeared to affect 7H 11 Id expression in the majority 
of treated mice, and the presence of the Id in high levels  shortly after challenge was 
associated with immunity. 
Expression of 11D5 and B7B1 Id.  The contribution of the 11D5 Id to the immunity 
observed is more difficult to ascertain because it is normally expressed earlier and in 
higher levels in response to WRATat 1.1 infection than the 7H 11 Id (Fig. 3 b; controls, 
normal infection). In this case, the sera examined before infection provide the clearest 
indication of whether the anti-Id treatment  affected the expression of the  11D5 Id. 
This Id was in fact more frequently found, and in higher levels, before infection in the 
protected and switched groups than in the anti-Id-treated nonimmune mice. Although 
there were mice within each affected group in which the Id remained silent through- 
out, it is possible that enhanced expression of both the 7H11 and  11D5  Id mediated 
the more complete immunity in the majority of mice that were protected. This point 
is  addressed  in  the  experiment  to  be  described  in  which  the  anti-7Hll  Id  was 
administered alone. 
Finally, the B7B 1 Id also arose normally in response to WRATat 1.1 infection and 
generally was detectable early on (Fig.  3 c). It did not, however, appear to be readily DAVID L.  SACKS, KLAUS M.  ESSER, AND ALAN SHER  1113 
inducible by anti-Id, as it was only rarely detected before infection, and then with no 
greater frequency in the immune than anti-Id-treated nonimmune mice. Thus, there 
is no evidence that the B 7B 1 Id contributed to the anti-Id-induced immunity observed. 
Immunization  with  Anti-7Hll  Id Alone.  In  this  experiment,  mice were  given  1 ~g 
IBC of the IgG1 fraction of the anti-7H11  Id or normal SJL IgG1 followed 2 wk later 
by an identical dose. Mice were challenged in another 2 wk with either WRATat  1.1, 
as  before, or with  a  VAT non-cross-reactive  T.  rhodesiense clone  NIHTat  1.  Of the 
mice infected  with  the  WRATat  1.1,  all  10  control  mice had  typical  infections  in 
which the WRATat  1.1  VAT was expressed on almost all parasites in the first peak. 
The 7H 11  Id was not detected in these mice until 2 wk postinfection, as before (Fig. 
4). None of the mice treated with the two doses of anti-Id were completely protected. 
However, six of nine mice did demonstrate VAT switching, and their peak parasitem- 
ias  were  delayed  by  a  day,  as  previously  observed.  In  addition,  all  six  mice  had 
detectable 7H11  Id 3 d postinfection (Fig. 4), although the levels were less than those 
detected in the previous experiment. Thus, the failure to induce complete protection 
in any of these animals might have been the result of the administration of only the 
one  anti-Id  or  to  the  insufficiently  high  concentration  at  which  the  one  Id  was 
induced. 
Of the  mice  treated  with  anti-Id  and  then  challenged  with  heterologous  clone 
NIHTat  1,  none  experienced  any modulation  of their  primary parasitemias.  This 
occurred despite enhanced levels of the 7H11 Id in the treated group, either before or 
3 d  after infection (Fig. 4). The Id was not found in response to NIHTat 1 infection 
in control mice. Thus, the immunity or partial immunity induced  by anti-7H11  Id 
was specific for the parasite bearing the VAT for which the Id had specificity. 
Discussion 
In these studies, we demonstrated that administration of anti-VAT anti-Id to mice, 
in  the absence of antigen,  can  induce  immunity against  subsequent  infection  with 
African  trypanosomes bearing  the  homologous VAT.  The  immunity is manifested 
either  as  complete  protection,  reduced  primary  parasitemia,  or  selection  against 
parasites bearing the original VAT. The immunity appears to be specific in so far as 
the anti-Id treatment had no effect on the outcome of infection with a  heterologous 
clone of T. rhodesiense. 
When three anti-VAT anti-Id were administered simultaneously, immunity could 
be induced in nearly two-thirds of those treated. One Id (7H1 I) was found selectively 
3  d  after challenge in animals displaying immunity but was absent  in control mice 
and  animals  that  had  been  treated  with  anti-Id  but  failed  to  display  immunity. 
Administration of the anti-7H11  Id alone led exclusively to VAT switching in two- 
thirds of those treated. Again, the effect was associated with the more rapid expression 
of the 7H11  Id within 3 d  after challenge. The effects of the anti-11D5 and B7B1  Id 
administered alone are currently under study. However, the more frequent detection 
of the 11D5 Id before challenge in the protected group in particular does suggest that 
the successful induction  of both the 7H 11  and  11D5 Id might have been responsible 
for their complete immunity. The inability to completely protect mice with anti-7H 11 
Id alone supports this view, although the levels of the 7H 11 Id induced in those mice 
were lower in this case. It is not clear why two doses of the anti-7H11  Id should have 
been less effective than the one, nor is it clear why the administration of anti-B7B 1 Id a  EXPRESSION  OF 7Hll  IDIOTYPE 
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Fro.  3.  Expression of individual  Id  in  serum after anti-Id administration and  infection.  Id 
concentrations were determined in a competitive RIA standardized with known concentrations of 
purified homologous Id as inhibitors. Lines represent levels in individual mice grouped according to 
outcome of primary parasiternia. Group A, normal SJL IgGl; group C, 250 ng IgGa anti-Id; group 
D, 1 ,ttg IgGl anti-Id; group E, 4 #g IgGl anti-Id. 
in particular  should have had so little effect  on subsequent  B7B1  Id expression.  The 
differences do suggest that the dose and kinetics of anti-Id administration  will have to 
be rigorously explored  for each  Id whose manipulation  is sought  to optimize desired 
biological effects. The source and class ofanti-Id might dictate additional  refinements 
or constraints. 
Administration of anti-Id antibodies has generally been studied in terms of its effect 
on Id expression  in subsequent  immune response to a specified,  controlled  amount of 
antigen.  This  sort  of analysis  is  precluded  in  these  studies  because  any  immunity 
induced  by anti-Id  before  infection  will  generally  reduce  the  amount  of antigen  to 
which  the  immune  system  is  subsequently  exposed.  Thus,  immune  mice  generally 
develop considerably lower anti-VAT antibody titers after infection than nonimmune 
mice.  We  determined  Id  levels  before  and  early  in  infection  as  well  as  2  wk  after 
infection, when the anti-VAT antibody response is normally optimum. The induction 
of antigen binding Id-bearing molecules by anti-Id in the absence of antigen exposure 
has  already  been  demonstrated  by Bluestone  et  al.  (10).  We  also  found  Id  induced 
before antigen exposure, and it was more frequently found in mice that then displayed 1116  IMMUNIZATION  WITH  ANTI-IDIOTYPIC  ANTIBODIES 
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Fro.  4.  Expression of 7H11  Id in serum after administration of anti-7H11  Id and infection with 
WRATat 1.1 or NIHTat  1. Id concentrations were determined as in Fig. 3. Group A, normal SoIL 
IgGl, WRATat  1.1 infected; group B, IgG1 anti-7Hll Id, WRATat  1.1 infected; group C, normal 
SJL IgG], NIHTat  1 infected; group D, IgG1 anti-7Hl 1-Id, NIHTat  1 infected. 
some immunity.  However, the more striking association appears to have been with 
71-tll  Id,  detectable just  after  infection,  at  a  time  when  it  had  not  yet  reached 
detectable levels in infected control mice. Thus, the immunity might not simply have 
been mediated by pre-existing antibody, but may have also resulted from the rapid 
activation by antigen of Id-bearing memory clones, established as a  result of anti-Id 
immunization. The higher levels in anti-Id-treated mice of the 7H11 Id, detectable 3 
d after WRATat  1.1 infection relative to NIHTat 1 infection, sUpports this view (Fig. 
4). 
At present, we are unable to restrict the detection of Id-bearing molecules to those 
that also have demonstrable antigen-binding  activity. Inclusion of parasite antigens 
in  our  assays  has  repeatedly  resulted  in  high  nonspecific  binding,  which  obscures 
detection of antibody below 0.5-1/~g/ml.  Therefore, the possibility that the admin- 
istration  of  anti-Id  has  led  to  the  production  of  Id-bearing  nonantigen-binding 
molecules,  as reported elsewhere  (8), cannot  be excluded.  However, this would  not 
explain the association of selective Id expression with immunity. 
Can  Id  induction  offer  an  alternative  approach  toward  immunization  against 
microbial agents in general? We find it encouraging that manipulation of one or two 
minor idiotypic clones can have a  biological effect. Anti-Id immunization  could be 
advantageous  in  protecting  against  parasites  whose  target  antigens  are difficult  to DAVID L.  SACKS, KLAUS M.  ESSER, AND ALAN SHER  1117 
isolate  in  sufficient  quantity  to  permit  conventional  vaccine  development.  As  a 
practical approach to prevention of African trypanosomiasis, anti-Id-induced immu- 
nity to a  restricted set of blood form trypanosome VAT is clearly not suitable.  The 
number of different  antigen  types  that  the  parasites  can  express  are  prohibitively 
large. However, the observation that within the insect vector trypanosomes revert to 
a  limited  and  relatively constant  set  of metacyclic VAT  suggests  that  these  VAT 
might  be  a  more  hopeful  target  for  Id  manipulation  (25).  Immunization  against 
malaria sporozoites (26)  might also benefit from this approach. The recent develop- 
ment of techniques for generating human monoclonal antibodies (27) suggests that in 
the  future  monoclonal  protective antibodies  as well  as anti-Id antibodies  could  be 
generated from human lymphocytes, thereby allowing the use of isologous immuno- 
globulins for the induction of Id in man. 
Summary 
Anti-idiotypic (anti-Id) antibodies were raised against three protective monoclonal 
antibodies,  each with  specificity for the  variable antigen  type  (VAT)  of a  clone of 
T~ypanosoma rhodesiense. The IgGa fractions of each were pooled and administered to 
BALB/e mice 3-4 wk before homologous challenge. The course of primary parasitemia 
was  altered  in  19  of 30  anti-Id-treated  animals.  The  immunity  was  manifested  as 
either:  (a)  complete  protection,  (b)  reduced  parasitemia,  or  (c)  selection  against 
parasites bearing the original VAT. The three idiotypes (Id) were found in variable 
levels in serum during the course of infection in control animals. However, in all anti- 
Id-treated mice that displayed immunity, one Id in particular (7H 11) was detectable 
much earlier in infection and in higher levels than in control mice or anti-Id-treated, 
nonimmune mice. Six of nine mice treated with the anti-7H 11 Id alone also displayed 
immunity,  manifested  in  this case exclusively as selection against  parasites bearing 
the original VAT. The effect was again associated with the more rapid appearance of 
the Id after infection.  Specificity of the anti-Id-induced immunity was supported by 
the failure of anti-7H11  Id treatment to alter the course of infection with a heterolo- 
gous clone of T.  rhodesiense. To our knowledge, this is the first report of the antigen- 
independent  induction of antimicrobial immunity using anti-Id antibodies. 
We thank D. H. Sachs for review of the manuscript and Mary Watson for secretarial assistance. 
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